Does the media prefer ROIV or SYRE?

In the previous week, Roivant Sciences had 10 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 9 mentions for Spyre Therapeutics. Roivant Sciences' average media sentiment score of 1.28 beat Spyre Therapeutics' score of 0.77 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 16 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SYRE or BNTX?

In the previous week, BioNTech had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 15 mentions for BioNTech and 9 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.77 beat BioNTech's score of 0.51 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or SYRE more profitable?

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Spyre Therapeutics' return on equity of -42.88% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Spyre Therapeutics N/A -42.88% -27.76%

Does the media prefer INSM or SYRE?

In the previous week, Insmed had 4 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for Insmed and 9 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 1.33 beat Spyre Therapeutics' score of 0.77 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRNA or SYRE?

In the previous week, Moderna had 43 more articles in the media than Spyre Therapeutics. MarketBeat recorded 52 mentions for Moderna and 9 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.77 beat Moderna's score of 0.46 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 18 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VTRS or SYRE?

In the previous week, Spyre Therapeutics had 3 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Spyre Therapeutics and 6 mentions for Viatris. Spyre Therapeutics' average media sentiment score of 0.77 beat Viatris' score of 0.39 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Spyre Therapeutics (SYRE) Competitors

$102.21 +7.28 (+7.67%)

As of 02:09 PM Eastern

Compare

SYRE vs. ROIV, BNTX, INSM, MRNA, and VTRS

Should you buy Spyre Therapeutics stock or one of its competitors? MarketBeat compares Spyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyre Therapeutics include Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS).

How does Spyre Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Roivant Sciences currently has a consensus price target of $33.59, indicating a potential downside of 2.61%. Spyre Therapeutics has a consensus price target of $101.42, indicating a potential downside of 0.78%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, meaning that its stock price is 203% more volatile than the broader market.

In the previous week, Roivant Sciences had 10 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 9 mentions for Spyre Therapeutics. Roivant Sciences' average media sentiment score of 1.28 beat Spyre Therapeutics' score of 0.77 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	16 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spyre Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,003.34	-$299.77M	-$0.60	N/A
Spyre Therapeutics	$890K	10,099.46	-$155.20M	-$2.08	N/A

Summary

Spyre Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to BioNTech?

Spyre Therapeutics (NASDAQ:SYRE) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Spyre Therapeutics presently has a consensus target price of $101.42, suggesting a potential downside of 0.78%. BioNTech has a consensus target price of $129.13, suggesting a potential upside of 41.31%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Spyre Therapeutics has a beta of 3.03, indicating that its share price is 203% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Spyre Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
BioNTech	-44.39%	-5.30%	-4.62%

In the previous week, BioNTech had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 15 mentions for BioNTech and 9 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.77 beat BioNTech's score of 0.51 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher earnings, but lower revenue than BioNTech. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,099.46	-$155.20M	-$2.08	N/A
BioNTech	$3.25B	7.12	-$1.29B	-$5.88	N/A

Summary

Spyre Therapeutics and BioNTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Insmed has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, indicating that its stock price is 203% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Spyre Therapeutics' return on equity of -42.88% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Spyre Therapeutics	N/A	-42.88%	-27.76%

In the previous week, Insmed had 4 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for Insmed and 9 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 1.33 beat Spyre Therapeutics' score of 0.77 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed presently has a consensus price target of $209.35, suggesting a potential upside of 111.52%. Spyre Therapeutics has a consensus price target of $101.42, suggesting a potential downside of 0.78%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Spyre Therapeutics has lower revenue, but higher earnings than Insmed. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$819.56M	26.18	-$1.28B	-$5.75	N/A
Spyre Therapeutics	$890K	10,099.46	-$155.20M	-$2.08	N/A

Summary

Spyre Therapeutics beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Spyre Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Moderna presently has a consensus price target of $42.13, suggesting a potential downside of 26.29%. Spyre Therapeutics has a consensus price target of $101.42, suggesting a potential downside of 0.78%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

75.3% of Moderna shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Moderna had 43 more articles in the media than Spyre Therapeutics. MarketBeat recorded 52 mentions for Moderna and 9 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.77 beat Moderna's score of 0.46 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	18 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral
Spyre Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has lower revenue, but higher earnings than Moderna. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	11.67	-$2.82B	-$7.99	N/A
Spyre Therapeutics	$890K	10,099.46	-$155.20M	-$2.08	N/A

Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

Summary

Spyre Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Spyre Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.44	-$3.51B	-$0.26	N/A
Spyre Therapeutics	$890K	10,099.46	-$155.20M	-$2.08	N/A

79.9% of Viatris shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, indicating that its share price is 203% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 3 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Spyre Therapeutics and 6 mentions for Viatris. Spyre Therapeutics' average media sentiment score of 0.77 beat Viatris' score of 0.39 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris presently has a consensus target price of $17.50, indicating a potential downside of 1.05%. Spyre Therapeutics has a consensus target price of $101.42, indicating a potential downside of 0.78%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Spyre Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Viatris on 13 of the 17 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRE vs. The Competition

Export

Metric	Spyre Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.98B	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-49.12	7.36	279.98	25.51
Price / Sales	10,099.46	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	14.18	17.18	11.15	6.35
Net Income	-$155.20M	-$12.52M	$3.48B	$347.60M
7 Day Performance	2.25%	2.48%	2.51%	3.14%
1 Month Performance	17.99%	-5.41%	-2.78%	-2.08%
1 Year Performance	532.50%	51.14%	64.32%	21.27%

Spyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRE Spyre Therapeutics	1.9936 of 5 stars	$102.21 +7.7%	$101.42 -0.8%	+483.8%	$8.98B	$890K	N/A	73	Gap Up
ROIV Roivant Sciences	1.6167 of 5 stars	$33.84 -2.5%	$33.59 -0.7%	+194.6%	$24.34B	$8.26M	N/A	860	Positive News Upcoming Earnings
BNTX BioNTech	3.9387 of 5 stars	$92.45 +1.5%	$129.13 +39.7%	-14.1%	$23.38B	$2.81B	N/A	7,807	Trending News Gap Down
INSM Insmed	3.8926 of 5 stars	$104.13 -0.6%	$209.35 +101.0%	-9.4%	$22.57B	$606.42M	N/A	1,664	Positive News Upcoming Earnings
MRNA Moderna	1.4943 of 5 stars	$55.81 +0.3%	$40.00 -28.3%	+99.8%	$22.14B	$2.20B	N/A	4,700	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRE) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Competitors

SYRE vs. ROIV, BNTX, INSM, MRNA, and VTRS

How does Spyre Therapeutics compare to Roivant Sciences?

Summary

How does Spyre Therapeutics compare to BioNTech?

Summary

How does Spyre Therapeutics compare to Insmed?

Summary

How does Spyre Therapeutics compare to Moderna?

Summary

How does Spyre Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Competitors

SYRE vs. ROIV, BNTX, INSM, MRNA, and VTRS

How does Spyre Therapeutics compare to Roivant Sciences?

Do analysts recommend ROIV or SYRE?

Is ROIV or SYRE more profitable?

Which has more risk & volatility, ROIV or SYRE?

Does the media prefer ROIV or SYRE?

Do insiders and institutionals believe in ROIV or SYRE?

Which has higher valuation and earnings, ROIV or SYRE?

Summary

How does Spyre Therapeutics compare to BioNTech?

Do analysts recommend SYRE or BNTX?

Which has more risk and volatility, SYRE or BNTX?

Do insiders & institutionals hold more shares of SYRE or BNTX?

Is SYRE or BNTX more profitable?

Does the media refer more to SYRE or BNTX?

Which has better earnings & valuation, SYRE or BNTX?

Summary

How does Spyre Therapeutics compare to Insmed?

Which has more risk and volatility, INSM or SYRE?

Do insiders and institutionals have more ownership in INSM or SYRE?

Is INSM or SYRE more profitable?

Does the media prefer INSM or SYRE?

Do analysts rate INSM or SYRE?

Which has stronger earnings and valuation, INSM or SYRE?

Summary

How does Spyre Therapeutics compare to Moderna?

Is MRNA or SYRE more profitable?

Do analysts prefer MRNA or SYRE?

Do insiders & institutionals have more ownership in MRNA or SYRE?

Does the media refer more to MRNA or SYRE?

Which has stronger earnings & valuation, MRNA or SYRE?

Which has more volatility & risk, MRNA or SYRE?

Summary

How does Spyre Therapeutics compare to Viatris?

Which has stronger valuation & earnings, VTRS or SYRE?

Do insiders & institutionals have more ownership in VTRS or SYRE?

Which has more volatility & risk, VTRS or SYRE?

Does the media refer more to VTRS or SYRE?

Do analysts prefer VTRS or SYRE?

Is VTRS or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools